TNFRSF17 and plasma cell myeloma: For multiple myeloma (MM), CARTs targeting the B cell maturation antigen (BCMA) (50–53) and for acute myeloid leukemia (AML) CARTs targeting CD33 (54), CD123 (55, 56) or CLL-1 (57) are under evaluation.